Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD

Journal of Clinical Psychiatry

Volumn 72, Issue 10, 2011, Pages 1366-1375

  Waxmonsky, James G ^a,c   Waschbusch, Daniel A ^a,c   Glatt, Stephen J ^b   Faraone, Stephen V ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LISDEXAMFETAMINE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER RATING SCALE IV; CLINICAL GLOBAL IMPRESSION SCALE; DEMOGRAPHY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG RESPONSE; HUMAN; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL (TOPIC); PLACEBO EFFECT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 80054924627     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m05979pur     Document Type: Article

References (59)

1. Stewart-Williams S, Podd J. The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull. 2004;130(2):324-340. doi:10.1037/03-2909.130.2.324 PubMed (Pubitemid 38317814)
2. Koshi EB, Short CA. Placebo theory and its implications for research and clinical practice: a review of the recent literature. Pain Pract. 2007;7(1): 4-20. doi:10.1/j.153-250.207.0104.x PubMed
3. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59(1):565-590. doi:10.146/anurev.psych.59.1306.095941 PubMed
4. Brown WA. Understanding and using the placebo effect. Psychiatr Times. 2006;23(11):15-17.
5. Waschbusch DA, Pelham WE Jr, Waxmonsky J, et al. Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2009;30(2):158-168. doi:10.1097/DBP.0b013e31819f1c15 PubMed
6. Khan A, Kolts RL, Rapaport MH, et al. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med. 2005;35(5):743-749. doi:10.1017/S0329170403873 PubMed (Pubitemid 40716438)
7. Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol. 2002;5(3):193-197. doi:10.1017/S14614570202912 PubMed
8. Emslie GJ. Understanding placebo response in pediatric depression trials. Am J Psychiatry. 2009;166(1):1-3. doi:10.176/api.ajp.208.08101541 PubMed
9. Khan A, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res. 2008;42(10):791-796. doi:10.1016/j.jpsychires.207.10.04 PubMed (Pubitemid 351787740)
10. Pelham WE Jr, Fabiano GA, Massetti GM. Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. J Clin Child Adolesc Psychol. 2005;34(3):449-476. doi:10.1207/s1537424jcp3403-5 PubMed (Pubitemid 41355524)
11. Owens JS, Goldfine ME, Evangelista NM, et al. A critical review of self-perceptions and the positive illusory bias in children with ADHD. Clin Child Fam Psychol Rev. 2007;10(4):335-351. doi:10.107/s10567-07-027-3 PubMed
12. Barkley RA. ADHD in adults: developmental course and outcome of children with ADHD, and ADHD in clinic-referred adults. In: Barkley RA, ed. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd ed. New York, NY: Guilford Press; 2006:248-296.
13. Waxmonsky JG, Gnagy EM, O'Connor B, et al. Prevalence and Predictive Factors of Bipolar Disorder in Young Adults With Attention-Deficit/ Hyperactivity Disorder. 160th Annual Meeting of the American Psychiatric Association. Washington, DC: American Psychiatric Press; 2007:274.
14. Waxmonsky J, Waschbusch DA, Pelham WE, et al. Effects of atomoxetine with and without behavior modification on the school and home functioning of children with and without ADHD. J Clin Psychiatry 2010; 71(11):1535-1551. PubMed
15. Ottenbacher KJ, Cooper HM. Drug treatment of hyperactivity in children. Dev Med Child Neurol. 1983;25(3):358-366. doi:10.1/j.1469-8749.1983.tb1372.x PubMed (Pubitemid 13095892)
16. Ullmann RK, Sleator EK. Responders, nonresponders, and placebo responders among children with attention deficit disorder: importance of a blinded placebo evaluation. Clin Pediatr (Phila). 1986;25(12):594-599. doi:10.17/0928602501201 PubMed (Pubitemid 17212778)
17. Sandler AD, Bodfish JW. Open-label use of placebos in the treatment of ADHD: a pilot study. Child Care Health Dev. 2008;34(1):104-110. PubMed
18. Newcorn JH, Sutton VK, Zhang S, et al. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder [published online ahead of print October 23, 2009]. J Am Acad Child Adolesc Psychiatry. PubMed
19. Cheng JYW, Chen RYL, Ko JSN, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescentsmeta- analysis and meta-regression analysis. Psychopharmacology (Berl). 2007;194(2):197-209. doi:10.107/s0213-07-0840-x PubMed (Pubitemid 47457955)
20. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebocontrolled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981-989. doi:10.1016/j.biopsych.207.1.08 PubMed
21. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-835. doi:10.1016/j.biopsych.205.09.01 PubMed
22. Spencer TJ, Adler LA, McGough JJ, et al. Adult ADHD Research Group. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007; 61(12):1380-1387. doi:10.1016/j.biopsych.206.07.032 PubMed (Pubitemid 46855767)
23. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attentiondeficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160(1): 82-90. doi:10.101/archpedi.160.1.82 PubMed (Pubitemid 43042140)
24. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120. doi:10.1016/S06-323(02)01671-2 PubMed (Pubitemid 36126473)
25. Bridge JA, Birmaher B, Iyengar S, et al. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry. 2009;166(1):42-49. doi:10.176/api.ajp.208.08020247 PubMed
26. Kowatch RA, Carmody TJ, Emslie GJ, et al. Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study. J Affect Disord. 1999;54(3):269-276. doi:10.1016/S0165-0327(98)0205-5 PubMed (Pubitemid 29329435)
27. Cohen D, Consoli A, Bodeau N, et al. Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders. J Child Adolesc Psychopharmacol. 2010;20(1):39-47. doi:10.1089/cap.209.047 PubMed
28. Khan A, Brown WA. The placebo enigma in antidepressant clinical trials. J Clin Psychopharmacol. 2001;21(2):123-125. doi:10.1097/04714-201040-01 PubMed (Pubitemid 32221047)
29. Porro CA. Open your mind to placebo conditioning. Pain. 2009; 145(1-2):2-3. doi:10.1016/j.pain.209.06.01 PubMed
30. Sherman R, Hickner J. Academic physicians use placebos in clinical practice and believe in the mind-body connection. J Gen Intern Med. 2008;23(1):7-10. doi:10.107/s1606-07-032-z PubMed
31. Rapport MD, Kofler MJ, Coiro MM, et al. Unexpected effects of methylphenidate in attention-deficit/hyperactivity disorder reflect decreases in core/secondary symptoms and physical complaints common to all children. J Child Adolesc Psychopharmacol. 2008;18(3):237-247. doi:10.1089/cap.207.0140 PubMed
32. Adler LA, Goodman DW, Kollins SH, et al.; 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-1373. doi:10.408/JCP.v69n0903 PubMed
33. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, doubleblind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450-463. doi:10.1016/S0149-2918(07)8083-X PubMed (Pubitemid 46924786)
34. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970-976. doi:10.1016/j.biopsych.207.04.015 PubMed (Pubitemid 47562371)
35. DuPaul GJ, Reid R, Power TJ, et al. ADHD Rating Scale-IV. New York, NY: Guilford; 1999.
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
37. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980-988. doi:10.1097/04583-197070-021 PubMed (Pubitemid 27272932)
38. Guy W. ECDEU Assessment Manual For Psychopharmacology. Washington, DC: Department of Health, Education and Welfare; 1976.
39. Adler LA, Spencer T, Faraone SV, et al. Validity of pilot adult ADHD Self-Report Rating Scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry. 2006;18(3):145-148. doi:10.1080/104012306080107 PubMed (Pubitemid 44576434)
40. StataCorp. Stata Statistical Software: Release 9.2 [computer program]. College Station, TX: StataCorp LP; 2005.
41. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45. doi:10.1371/journal.pmed.05045 PubMed
42. Owens EB, Hinshaw SP, Kraemer HC, et al. Which treatment for whom for ADHD? moderators of treatment response in the MTA. J Consult Clin Psychol. 2003;71(3):540-552. doi:10.1037/02-06X.71.3.540 PubMed (Pubitemid 36605344)
43. Arnold LE, Elliot M, Sachs L, et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14-month outcome in ADHD. J Consult Clin Psychol. 2003;71(4):713-727. doi:10.1037/02-06X.71.4.713 PubMed (Pubitemid 36897405)
44. Egger HL, Angold A, Costello EJ. Headaches and psychopathology in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1998; 37(9):951-958. doi:10.1097/04583-198090-015 PubMed (Pubitemid 28406742)
45. Masi G, Favilla L, Millepiedi S, et al. Somatic symptoms in children and adolescents referred for emotional and behavioral disorders. Psychiatry. 2000;63(2):140-149. PubMed (Pubitemid 30642065)
46. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86(2): 184-192. PubMed (Pubitemid 20238848)
47. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100(4):662-666. doi:10.1542/peds.10.4.62 PubMed (Pubitemid 27425991)
48. Vetter VL, Elia J, Erickson C, et al. American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-2423. doi:10.161/CIRCULATIONAHA.107.189473 PubMed (Pubitemid 351653546)
49. Pearl PL, Weiss RE, Stein MA. Medical mimics: medical and neurological conditions simulating ADHD. Ann N Y Acad Sci. 2001;931(1): 97-112. doi:10.1/j.1749-632.201.tb0575.x PubMed (Pubitemid 32612783)
50. Lubke GH, Hudziak JJ, Derks EM, et al. Maternal ratings of attention problems in ADHD: evidence for the existence of a continuum. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1085-1093. doi:10.1097/CHI.0b013e3181ba3db PubMed
51. Lubke GH, Muthén BO, Moilanen IK, et al. Subtypes versus severity differences in attention-deficit/hyperactivity disorder in the Northern Finnish Birth Cohort. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1584-1593. doi:10.1097/chi.0b013e31815750d PubMed (Pubitemid 350146523)
52. Quitkin FM. Placebos, drug effects, and study design: a clinician's guide. Am J Psychiatry. 1999;156(6):829-836. PubMed (Pubitemid 29260335)
53. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 2000;57(4):311-317. doi:10.101/archpsyc.57.4.31 PubMed (Pubitemid 30202315)
54. Greenhill LL, Newcorn JH, Gao H, et al. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. J Am Acad Child Adolesc Psychiatry. 2007;46(5):566-572. doi:10.1097/chi.0b013e318035ad1 PubMed (Pubitemid 46642573)
55. Lahey BB, Pelham WE, Loney J, et al. Instability of the DSM-IV Subtypes of ADHD from preschool through elementary school. Arch Gen Psychiatry. 2005;62(8):896-902. doi:10.101/archpsyc.62.8.896 PubMed (Pubitemid 41126884)
56. Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York, NY: Guilford Press; 2008.
57. Biederman J, Lopez FA, Boellner SW, et al. A randomized, doubleblind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110(2 Pt 1):258-266. doi:10.1542/peds.10.2.258 PubMed (Pubitemid 34833008)
58. Wolraich ML, Greenhill LL, Pelham WE, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attentiondeficit/ hyperactivity disorder. Pediatrics. 2001;108(4):883-892. doi:10.1542/peds.108.4. 83 PubMed (Pubitemid 32947657)
59. Khan A, Schwartz K, Kolts RL, et al. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol Psychiatry. 2007;62(1):65-71. doi:10.1016/j.biopsych.206.08.036 PubMed (Pubitemid 46898225)